Overview

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Status:
Not yet recruiting
Trial end date:
2026-12-14
Target enrollment:
Participant gender:
Summary
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with Olaparib or Talazoparib.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Artios Pharma Ltd
Treatments:
Olaparib
Talazoparib